Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pharmaceutical company Pharmaxis has increased its manufacturing capacity with the signing of an agreement for the construction of a new facility at Frenchs Forest, Sydney. Following completion of construction in the fourth quarter of 2008, Pharmaxis may lease the 7,000 square meter manufacturing and research facility for a term of 15 years with two options to renew of five years each.
Subscribe to our email newsletter
The purpose built facility will include an expanded manufacturing plant with initial capacity sufficient to supply Bronchitol to approximately 40,000 patients per year. Pharmaxis is developing Bronchitol for the treatment of diseases including cystic fibrosis, bronchiectasis and chronic bronchitis.
Construction of the key manufacturing equipment commenced in Denmark earlier in the year. In addition to manufacturing, the facility will house the commercial, clinical and administration functions of the company as well as the drug discovery group which is currently located at North Ryde. The premises will provide further opportunities to expand initial capacity in a modular fashion.